Surrozen Inc Stock Price, News & Analysis

Surrozen (Nasdaq: SRZN) announced an inducement stock option grant to newly appointed CFO Andrew P. Maleki.

On November 6, 2025 the board approved options covering 50,000 shares under the company’s 2025 Equity Inducement Plan, exercisable at $12.94 per share (Nasdaq closing price on November 12, 2025). The options vest over four years with 25% vesting on the first anniversary and the remainder vesting monthly thereafter, subject to continuous service.

The awards were granted as an inducement material to acceptance of employment in accordance with Nasdaq Listing Rule 5635(c)(4).

Surrozen (Nasdaq: SRZN) reported third quarter 2025 results and a business update on Nov 7, 2025. Key clinical and corporate points: the company remains focused on its ophthalmology pipeline with lead candidates SZN-8141 and SZN-8143 and is on track to submit an IND for SZN-8141 in 2026. Leadership: Andrew Maleki joined as CFO; Charles Williams will continue as COO.

Q3 financials: cash $81.3M, collaboration revenue $0 (vs $10.0M in Q3 2024), R&D $7.8M, G&A $4.1M, net loss $71.6M or ($8.36) per share; noncash losses included $40.7M tranche liability and $20.9M other expense.

Surrozen (Nasdaq: SRZN) will present at the Guggenheim 2nd Annual Healthcare Innovation Conference on November 12, 2025. Management will hold a fireside chat at 6:30 AM Pacific Time / 9:30 AM Eastern Time. Interested parties can listen to the audio webcast via the Investors section of Surrozen's website and a replay will be archived at www.surrozen.com. The presentation covers company developments in targeted Wnt pathway therapeutics for severe eye diseases and is intended for investors and healthcare stakeholders.

Surrozen (Nasdaq: SRZN), a biotechnology company focused on Wnt pathway therapeutics for severe eye diseases, has granted inducement stock options to four new non-executive employees. The grants, approved on September 2, 2025, cover 45,710 shares of common stock at an exercise price of $12.32 per share.

The stock options were awarded under Surrozen's 2025 Equity Inducement Plan in accordance with Nasdaq Listing Rule 5635(c)(4). The options vest over four years, with 25% vesting after the first year and the remainder vesting monthly thereafter, subject to continued employment.

Surrozen (Nasdaq: SRZN), a biotechnology company focused on developing targeted therapeutics for severe eye diseases through Wnt pathway modulation, has announced its participation in the upcoming H.C. Wainwright 27th Annual Global Investment Conference.

The presentation is scheduled for September 10, 2025, from 8:30 AM to 9:00 AM Pacific Time (11:30 AM to 12:00 PM Eastern Time). Investors can access the audio webcast through Surrozen's investor relations website, with a replay available afterward.

Surrozen (Nasdaq: SRZN), a biotechnology company focused on developing targeted therapeutics for the Wnt pathway with emphasis on severe eye diseases, has announced its participation in the Cantor Global Healthcare Conference 2025.

The company will participate in a fireside chat on September 4, 2025, from 8:00 - 8:30 AM Eastern Time. Investors can access the audio webcast through Surrozen's investor relations website, with a replay available afterward at www.surrozen.com.

Surrozen (NASDAQ:SRZN), a biotechnology company focused on Wnt pathway therapeutics for eye diseases, reported Q2 2025 financial results and significant organizational developments. The company ended Q2 with $90.4 million in cash, down from $101.6 million in Q1, and posted net income of $39.7 million ($2.55 per share).

Key developments include the appointment of Dr. Daniel Chao as VP of Clinical Development, formation of a Clinical Advisory Board with leading retinal specialists, and receipt of a U.S. patent for their SWAP™ technology. The company's lead candidates, SZN-8141 and SZN-8143, continue progressing, with an IND submission for SZN-8141 planned for 2026.

Research revenue was $1.0 million, while R&D expenses increased to $6.0 million from $5.3 million year-over-year. The significant net income was primarily driven by non-cash gains from changes in fair value of tranche liability and warrant liabilities.

Surrozen (Nasdaq: SRZN), a biotechnology company focused on developing targeted therapeutics that modulate the Wnt pathway for tissue repair and regeneration, particularly in severe eye diseases, has announced its participation in the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference.

The presentation will be available starting at 7:00 AM Eastern Time on Wednesday, August 13, 2025. Investors can access the audio webcast through Surrozen's investor relations website, with a replay available afterward.

Surrozen (NASDAQ: SRZN) has been granted U.S. Patent No. 12,297,278 for its SWAP™ technology, expanding its intellectual property portfolio in Wnt pathway therapeutics. The patent covers tetravalent, multi-specific Wnt surrogates that utilize antibody-based molecules to target key receptors in the Wnt pathway.

The company's patent portfolio now includes 6 U.S. patents, 10 international patents, and multiple pending applications. The newly granted patent specifically covers technology involving two Frizzled (Fzd) binding regions and two LRP5/6 binding regions, connected via linker moieties. Surrozen has demonstrated that multivalent binding to Fzd and LRP is crucial for maximal signaling through selective surrogate Wnt molecules.